Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical impo
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
05:14pm, Thursday, 28'th May 2026
Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, P
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its
US Agency Broadens Coverage Of Personalis Breast Cancer Test
02:22pm, Wednesday, 20'th May 2026
Personalis Inc. (NASDAQ:PSNL) received a favorable reimbursement decision that could make its cancer test available to more patients — and more likely to be paid for by Medicare.
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecu
Personalis to Participate in Upcoming Investor Events
04:01pm, Thursday, 14'th May 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
07:00am, Wednesday, 13'th May 2026
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare and Medicaid Services' (CMS)
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
06:00am, Wednesday, 13'th May 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecu
Personalis Q1 Earnings Call Highlights
05:08pm, Friday, 08'th May 2026
Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business an
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
04:11pm, Friday, 08'th May 2026
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
08:05pm, Thursday, 07'th May 2026
Personalis (PSNL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.18 per share a year ago.
Personalis Reports First Quarter Results and Recent Highlights
04:01pm, Thursday, 07'th May 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended Ma
Personalis to Announce First Quarter 2026 Financial Results
04:01pm, Thursday, 23'rd Apr 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results o
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
06:00am, Tuesday, 21'st Apr 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American As
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer da
